Introduction {#S1}
============

The central nervous system (CNS) is very susceptible to damage when its blood supply is compromised^[@R1]-[@R3]^. Accordingly, the CNS has numerous control systems to ensure adequate blood supply, including: 1) *neurovascular coupling*, whereby neuronal activity locally dilates blood vessels to increase blood flow via glutamate and NO signaling; 2) *metabolic coupling*, whereby energy systems (including O~2~) regulate neuronal activity and vessel diameter; and 3) *basal vascular tone*, whereby CNS-derived neuromodulators such as serotonin (5-HT), noradrenaline (NA) and dopamine produce widespread vasoconstriction (along with myogenic tone), which effectively conserves blood for locally active areas dilated by neurovascular coupling^[@R4]-[@R7]^. The latter phenomenon is analogous to the sympathetic control system in the periphery, where NA causes widespread vessel tone^[@R8],[@R9]^; though in the CNS neurons in the brainstem provide most of the NA and 5-HT, except for sympathetic innervation of large pial arteries^[@R10]-[@R14]^.

In the setting of severe spinal cord injury (SCI), vessels and neurons caudal to the injury survive, but lose monoamine innervation that normally arises primarily from brainstem neurons^[@R15]^. Although vessels directly damaged by SCI undergo well-documented plasticity at the injury epicenter^[@R16]-[@R18]^, including angiogenesis^[@R19]^, little is known about the uninjured vessels caudal to the site of the SCI, especially long after injury^[@R2]^. Considering that uninjured spinal neurons undergo remarkable adaptations that compensate for loss of supraspinal monoamine innervation after SCI^[@R15],[@R20],[@R21]^, we investigated whether vessels undergo similar adaptations. Normally, 5-HT and other monoamines in the spinal cord are synthesized exclusively in brainstem-derived axons, via enzymatic pathways such as the conversion of tryptophan to 5-HTP and then to 5-HT by the action of tryptophan-hydroxylase (TPH) and aromatic-[l]{.smallcaps}-amino-acid-decarboxylase (AADC), respectively^[@R14]^. After SCI, with the loss of the axons in which these enzymes are expressed, the levels of these enzymes are dramatically reduced, with one notable exception: spinal capillaries, which normally only weakly express AADC and lack other relevant enzymes such as TPH, markedly upregulate AADC expression caudal to the injury^[@R22],[@R23]^.

Although AADC activity alone is not sufficient for endogenous synthesis of 5-HT (and indeed vessels lack 5-HT after SCI^[@R14],[@R23],[@R24]^), AADC can directly synthesize trace amines (TAs; [Supplementary-Fig-1](#SD1){ref-type="supplementary-material"}), such as tryptamine and tyramine, from amino acids such as tryptophan and tyrosine. In general, the endogenous functions of TAs have remained largely elusive, especially in the spinal cord^[@R14],[@R25]-[@R27]^. TAs are not packaged or released in vesicles, lack a high affinity transporter, and are accordingly rapidly metabolized by monoamine oxidase (MAO), leaving only trace (nanomolar) quantities^[@R23],[@R25],[@R26]^. However, when AADC is present at high levels, as within capillaries after SCI, TAs are likely to reach the high micromolar concentrations of their precursor amino acids circulating in the blood^[@R28],[@R29]^, considering that amino acids are readily transported into all cells^[@R30]^. At these micromolar concentrations, TAs activate 5-HT~1~ receptors (tryptamine), α~2~-adrenergic receptors (tyramine, phenylethylamine)^[@R31],[@R32]^, and specialized TA associated receptors (TAARs)^[@R33]^, and have known effects on heart and mesentery vasculature^[@R34],[@R35]^. Thus, we hypothesized that TAs synthesized by AADC locally in capillaries might directly regulate vessel tone after SCI, replacing lost monoamine innervation.

Classically, CNS blood flow is thought to be controlled by smooth muscle cells (SMCs) of arterioles that constrict in response to vasoactive substances, including centrally-derived 5-HT and NA acting on 5-HT~1~ and α~2~-adrenergic receptors^[@R4],[@R10]-[@R12],[@R14],[@R36]-[@R42]^, via similar mechanisms that occur in the periphery^[@R9],[@R42]^. Arterioles branch to form small capillaries which lack SMCs, but which are associated with sparsely spaced pericytes that wrap around CNS capillaries^[@R41]^ ([Fig-1a](#F1){ref-type="fig"}). Although pericytes have diverse functions, including contributing to scar formation after SCI^[@R43]^, many pericytes are contractile, containing smooth-muscle α-actin (α-SMA) and contracting in response to monoamines^[@R4],[@R6],[@R41],[@R44]^. Indeed, pericytes have recently been shown to play a major role in both controlling normal CNS blood flow and the response to ischemic stroke^[@R6],[@R7],[@R14],[@R37],[@R44]-[@R46]^. Coincidentally, we noticed that when AADC is upregulated in capillaries after SCI, it is most intensely expressed in pericytes^[@R23]^. Thus, we explore here whether pericytes play a special role in regulating capillary tone and blood flow after SCI, by synthesis of TAs that replace lost monoamines.

Results {#S2}
=======

Endogenously produced trace amines (TAs) constrict capillaries at pericytes after SCI {#S3}
-------------------------------------------------------------------------------------

In the spinal cord of normal and injured rats, immunolabeling with the pericyte marker NG2 revealed pericytes spaced every ∼50 μm along capillaries ([Fig-1b](#F1){ref-type="fig"}), as previously described elsewhere in the brain^[@R6]^. These pericytes have a characteristic hemispherical soma, unlike astrocytes, endothelial cells or SMCs ([Fig-1a,b](#F1){ref-type="fig"}, [Supplementary-Fig-2](#SD1){ref-type="supplementary-material"}), allowing us to identify them morphologically, while imaging whole spinal cords maintained *in vitro*, using live tissue differential interference microscopy (DIC; [Fig-1c,d](#F1){ref-type="fig"})^[@R6]^. In spinal cords caudal to a chronic spinal transection, application of physiological concentrations of tryptophan, tyrosine or phenylalanine (10--100 μM)^[@R28],[@R29]^ induced tonic local constrictions of capillaries adjacent to pericytes ([Fig-1d,i](#F1){ref-type="fig"}; in 72%, 66% and 78% of pericytes, respectively), consistent with the notion that the increased expression of AADC in capillaries caudal to a SCI^[@R23]^ leads to production of TAs. Capillary regions without pericytes lacked constrictions ([Fig-1d](#F1){ref-type="fig"}), consistent with the concept that pericytes are responsible for the vasoconstrictions, as previously demonstrated in the uninjured CNS^[@R6],[@R45]^. The tryptophan-induced constrictions produced changes in vessel morphology and cord opacity, and widespread displacement of red blood cells (RBCs; [Supplementary Fig 3 and Video](#SD1){ref-type="supplementary-material"}). In summary, after SCI, application of tryptophan led to a decrease in capillary diameter adjacent to pericytes by ∼25%, halving the local cross-sectional area ([Fig-1i](#F1){ref-type="fig"}), which should severely impair blood flow.

The AADC inhibitor NSD1015 eliminated tryptophan-induced vasoconstriction ([Fig-1e,i](#F1){ref-type="fig"}), consistent with the conclusion that AADC conversion of tryptophan to tryptamine is responsible for inducing vasoconstriction. Indeed, exogenously applied tryptamine induced vasoconstrictions at 70% of pericytes, mimicking the effect of tryptophan, and tryptamine-induced vasoconstriction was resistant to NSD1015 ([Fig-1f,i](#F1){ref-type="fig"}). NSD1015 alone had no effect on vessel diameter ([Fig 1i](#F1){ref-type="fig"}), indicating that *in vitro* there is inadequate endogenous free tryptophan for AADC action (unlike *in vivo*, as described below). Tryptophan did not constrict arterioles after SCI ([Fig-1i](#F1){ref-type="fig"}), ruling out the possibility that endogenously produced tryptamine can constrict these vessels. Tryptophan had no effect on capillaries or arterioles in spinal cords from normal uninjured rats ([Fig-1h,i](#F1){ref-type="fig"}), consistent with the relative lack of vessel-associated AADC in uninjured spinal cords (as described below).

Trace amines activate 5-HT~1B~ and α~2~-adrenergic receptors to constrict capillaries {#S4}
-------------------------------------------------------------------------------------

We next tested whether TAs replace the function of monomines lost with injury by activating monoamine receptors. Indeed, tryptamine- and tryptophan-induced capillary vasoconstriction in chronic spinal rats were blocked by the selective 5-HT~1B/D~ receptor antagonist GR127935 ([Fig-1g,i](#F1){ref-type="fig"}), and were mimicked by the 5-HT~1B/D~ receptor agonist zolmitriptan ([Fig-1i](#F1){ref-type="fig"}), at doses consistent with zolmitriptan\'s moderate affinity for 5-HT~1B~ receptors, and not its high affinity for 5-HT~1D~ receptors^[@R20]^. Tyrosine-induced vasoconstriction (via AADC-mediated synthesis of tyramine) was blocked by the α~2~ receptor antagonist RX821002 ([Fig-1i](#F1){ref-type="fig"}). 5-HTP, which is converted to 5-HT by AADC, had mixed effects on capillaries, constricting them at low doses, consistent with action at the 5-HT~1B~ receptor, but dilating them at higher doses ([Fig-1i](#F1){ref-type="fig"}, [Supplementary-Fig-4](#SD1){ref-type="supplementary-material"}). In spinal cords from uninjured rats, 5-HT generally induced capillary constrictions at pericytes ([Fig-1i](#F1){ref-type="fig"}).

Mechanisms of pericyte action after SCI {#S5}
---------------------------------------

In the spinal cord from uninjured rats (or in the spinal cord rostral to the site of injury after SCI), AADC immunolabeling was predominantly in axons (descending monoamine fibers), whereas it was absent (or only weakly expressed) in most vessels, as previously detailed^[@R23]^ ([Supplemental Fig-5a](#SD1){ref-type="supplementary-material"}). In contrast, caudal to a spinal cord transection, AADC immunolabeling was highly upregulated in vessels and not generally present in axon tracts^[@R23]^ ([Supplementary Fig 5b](#SD1){ref-type="supplementary-material"}). Double immunolabeling with the pericyte markers CD13 or NG2 revealed that this vessel AADC expression was entirely co-localized with pericytes on capillaries, with more intense expression near the pericyte membrane, as compared to the cytoplasm, especially adjacent to the vessel wall (forming a flat disc; [Fig-2a,c,d](#F2){ref-type="fig"}; [Supplementary Figs 5-7](#SD1){ref-type="supplementary-material"}). In contrast, AADC was not co-expressed with an endothelial cell marker ([Supplementary Fig 6](#SD1){ref-type="supplementary-material"}), indicating a lack of endothelial AADC. AADC and its enzymatic products were present in capillary pericytes throughout the white and gray matter, including the dorsal horn and dorsal columns ([Fig-2a](#F2){ref-type="fig"}, [Supplementary Figs 5,8](#SD1){ref-type="supplementary-material"}). AADC immunolabeling was not seen on arteries or arterioles ([Fig 2a](#F2){ref-type="fig"}).

Immunolabeling for tryptamine revealed that this TA was endogenously expressed in capillaries caudal to the site of injury after an SCI, with dense punctate expression in the pericyte soma ([Fig 2b](#F2){ref-type="fig"}; [Supplementary Fig 7](#SD1){ref-type="supplementary-material"}). Furthermore, this tryptamine staining was eliminated by pretreatment of the rats with NSD1015 ([Supplementary Fig 7d](#SD1){ref-type="supplementary-material"}). These results are consistent with the concept that AADC in pericytes produce tryptamine from endogenous tryptophan ([Fig-2e](#F2){ref-type="fig"}). In contrast, tryptamine immunolabeling was largely absent from most capillaries rostral to the site of injury or in uninjured spinal cords ([Supplementary-Fig 7](#SD1){ref-type="supplementary-material"}). Immunolabeling for 5-HT~1B~ receptors revealed that these receptors were densely expressed on pericytes ([Fig-2g](#F2){ref-type="fig"}; [Supplementary-Figure 10](#SD1){ref-type="supplementary-material"}), where they could be readily activated by tryptamine synthesized locally by the pericyte itself ([Fig-2e](#F2){ref-type="fig"}).

Immunolabeling for 5-HT confirmed previous findings that 5-HT is completely absent caudal to the spinal cord transection ([Fig-2f](#F2){ref-type="fig"}, [Supplementary-Fig 8b](#SD1){ref-type="supplementary-material"})^[@R23]^. However, pre-treatment of these chronic spinal rats by injection of the 5-HT precursor 5-HTP led to pronounced 5-HT immunolabeling in the microvasculature ([Fig 2c,d](#F2){ref-type="fig"}; [Supplementary Fig-8a](#SD1){ref-type="supplementary-material"}). This 5-HT staining is eliminated by injection of an AADC blocker^[@R23]^, showing that the 5-HT is entirely produced by AADC and is a useful surrogate marker of AADC\'s ability to produce amines after SCI. This AADC product (5-HT staining) co-localized with pericyte AADC staining ([Fig-2d](#F2){ref-type="fig"}, and CD13or NG2 pericyte labelling), and accumulated densely in the cytoplasm of the pericyte soma, adjacent to patches of dense AADC labeling ([Fig-2d](#F2){ref-type="fig"}, [Supplementary Fig-9](#SD1){ref-type="supplementary-material"}), similar to tryptamine\'s localization. The mRNA expression of the pericyte marker CD13 was increased 45% caudal to the SCI, and expression of other pericyte signaling molecules was also altered, suggesting a proliferation of pericytes with SCI ([Supplementary-Fig-11](#SD1){ref-type="supplementary-material"}) ^[@R47]^.

Endogenous trace amines induce hypoxia after SCI {#S6}
------------------------------------------------

Considering that physiological concentrations of tryptophan constrict capillaries via endogenous TA production, we next examined blood flow *in vivo*. In the spinal cord below a chronic transection injury, the vasculature perfusion rate was half that in the cord above the injury or in normal spinal cords, as quantified by the time taken to fill all vessels with the vital dye methylene blue after intracardial injection ([Fig-3a,b](#F3){ref-type="fig"}). Furthermore, when we injected a fluorescent dextran into the blood, two-photon-fluorescence microscopy revealed that the flow rates in spinal capillaries were abnormally low after SCI ([Fig-3c](#F3){ref-type="fig"}), compared to in uninjured CNS^[@R48]^. Blocking TA production (with an AADC blocker; [Fig-3c](#F3){ref-type="fig"}) or action (with a 5-HT~1B~ receptor antagonist; [Fig-3b](#F3){ref-type="fig"}) restored blood flow to near normal rates (doubling flow), consistent with the concept that endogenous tryptophan acts via AADC to restrict capillary flow under *in vivo* conditions. In a control experiment, application of an NO donor to fully dilate vessels showed that the unconstricted vasculature had equal perfusion capacity in normal uninjured and SCI rats ([Fig-3b](#F3){ref-type="fig"}).

We next measured tissue oxygenation (pO~2~) *in vivo*. The spinal cord caudal to the site of injury was chronically hypoxic along its entire length (pO~2~ ≪ 20 mmHg^[@R49]-[@R51]^), with pO~2~ values caudal to the injury less than half of those rostral to the injury or of the uninjured spinal cord ([Fig-3d,e](#F3){ref-type="fig"}). Treatments that dilated the capillaries---inhibition of AADC or blockade of 5-HT~1B~ or α~2~-adrenergic receptors---restored normal pO~2~ caudal to the site of injury, while not affecting pO~2~ rostral to the site of injury ([Fig-3e,f](#F3){ref-type="fig"}). Tryptophan application itself did not alter pO~2~, likely because endogenous tryptophan levels in the CNS and circulation (∼50 μM)^[@R28],[@R29]^ are already well above the concentration that we found produces peak effects in the isolated spinal cord (10 μM; [Fig-1i](#F1){ref-type="fig"}). A short period of hyperoxia (1 min) in which the concentration of inhaled O~2~ was raised to 100% or 95% (with 5% CO~2~ to maintain breathing rate) rapidly increased arterial pO~2~ from ∼100 to ∼400 mmHg and accordingly increased spinal cord pO~2~ to well above normal ([Fig-3e](#F3){ref-type="fig"}, blue bar), demonstrating that caudal blood flow is inadequate to supply normal oxygenation without an artificial increase in arterial oxygen levels.

Unexpectedly, after this brief 1 min period of hyperoxic breathing, cord pO~2~ caudal to the site of injury remained elevated for 20 min, even though rostral to the injury the cord pO~2~ returned rapidly (within 1 min) to normal ([Fig-3e](#F3){ref-type="fig"}), as did breathing rate, exhaled CO~2~ and arterial pO~2~ (Methods). This prolonged elevation in cord pO~2~ caudal to the site of injury is likely due to the effect of increased oxygenation on raising neural activity (see below), which in turn triggers neurovascular coupling that dilates vessels and further increases oxygen and neural activity in a positive feedback loop (especially in the hyperexcitable cord after SCI^[@R15]^). Indeed, we observed prominent neurovascular coupling after SCI, caudal to the site of injury ([Supplementary-Fig-12](#SD1){ref-type="supplementary-material"}). Transient breathing of 100% O~2~ (1 min) likewise led to a prolonged (20 min) elevation in pO~2~ caudal to the site of injury, as did air with increased CO~2~ levels (10% CO~2~ in air for 30 s; because CO~2~ dilates vessels^[@R1]^) or even mild hypoxia (10% O~2~ in air for 1 min) ([Supplementary-Fig-13](#SD1){ref-type="supplementary-material"}).

Motor function is enhanced by blocking trace amine action and preventing hypoxia {#S7}
--------------------------------------------------------------------------------

To evaluate the functional effects of the impaired blood flow and chronic hypoxia after SCI, we recorded EMG activity (electromyography) in the paralyzed tail muscles of the awake chronic spinal rat (sacral transection)^[@R15]^. Treatments that dilated spinal capillaries---the receptor antagonists GR127935 or RX821002, or inhaled 10% CO~2~---increased spontaneous EMG activity ([Fig-4a-c,f](#F4){ref-type="fig"}). Likewise, treatments that indirectly increase spinal cord blood flow by systemically augmenting blood pressure (peripherally-acting dobutamine or vasopressin) also increased EMG activity ([Supplementary-Fig-14](#SD1){ref-type="supplementary-material"}). Transient hyperoxic breathing (95% O~2~ for 1 min) to increase spinal cord oxygenation by increasing arterial pO~2~ also increased spontaneous EMG activity, with effects lasting 20 min beyond the treatment period ([Fig-4d,f](#F4){ref-type="fig"}), consistent with the cord pO~2~ measurements ([Fig 3e](#F3){ref-type="fig"}). Each of these treatments also increased sensory-evoked EMG responses (long-lasting reflexes, LLRs in [Fig-4b-f](#F4){ref-type="fig"}), and increased the incidence of rhythmic locomotor-like bursting ([Fig-4d](#F4){ref-type="fig"}, blue thin line; [Supplementary-Fig-14](#SD1){ref-type="supplementary-material"}). Hyperoxia or hypercapnia produced similar increases in EMG when repeated at \>60 min intervals.

To rule out direct actions of TAs on neurons, we also examined motor activity and sensory-evoked motor responses (LLRs) in the ventral roots of isolated spinal cords from chronic spinal rats. The spinal cords were maintained *in vitro* in oxygenated artificial cerebrospinal fluid (nACSF), where vessels have no influence ([Supplementary-Fig-15a,b](#SD1){ref-type="supplementary-material"}). Notably, in these isolated cords, motor activity (LLRs) was not altered by treatment with NSD1015, GR127935, RX821002 ([Fig-4c](#F4){ref-type="fig"}) or tryptophan ([Supplementary-Fig-15d,e](#SD1){ref-type="supplementary-material"}). The lack of an effect of tryptophan indicates that TAs endogenously produced from tryptophan have no direct effect on neurons. Though exogenous application of high doses of TAs did increase LLRs, this effect was mediated by a different receptor subtype (blocked by 5-HT~2C~ receptor antagonist) than the monoamine receptors that control capillaries ([Supplementary-Fig-15f,i](#SD1){ref-type="supplementary-material"}). Furthermore, transient alteration of the pO~2~ of the ACSF in the *in vitro* preparation, from normoxic to hyperoxic levels, transiently altered motoneuron activity (LLRs; [Fig-4e,f](#F4){ref-type="fig"}): an increase in pO~2~ produced an increase in LLRs, consistent with a previous report^[@R52]^. However, this increase in LLRs did not outlast the O~2~ application, consistent with the concept that increased blood flow via neurovascular coupling mediates the sustained pO~2~ and LLRs observed *in vivo* after O~2~ breathing ([Fig-4e,f](#F4){ref-type="fig"}).

Locomotor function after SCI is improved by treatments that improve capillary blood flow {#S8}
----------------------------------------------------------------------------------------

To evaluate locomotion after SCI, we studied rats with a thoracic SCI, from either a severe contusion or a staggered hemisection injury ([Fig. 5a](#F5){ref-type="fig"}); the latter type of injury transects most descending axons, including removing 5-HT^[@R15],[@R53]^ ([Supplementary-Fig-16](#SD1){ref-type="supplementary-material"}). A month after these injuries, rats regained some voluntary hindlimb locomotor ability, though weight support was impaired, plantar foot placement was poor and step timing was slow, in part because of leg extensor spasms ([Fig-5b](#F5){ref-type="fig"}). In the lumbar region caudal to the injury, pO~2~ was hypoxic, significantly lower than rostral to the site of injury or in uninjured spinal cord ([Fig 5f-g](#F5){ref-type="fig"}). Dilation of capillaries with locally applied GR127935 or RX821002 restored near normal pO~2~ ([Fig 5f-g](#F5){ref-type="fig"}), with effects lasting as long as the drug was present (durations of 30 - 90 min were tested). Transient O~2~ breathing (95%, 90 s) likewise restored normal pO~2~, with effects lasting 20 min, as for the chronic spinal rats in [Fig 3](#F3){ref-type="fig"} ([Fig 5f-g](#F5){ref-type="fig"}). Intrathecal injection of GR127935 or NSD1015 to dilate capillaries, or transient O~2~ breathing, significantly improved walking ability ([Fig-5c-e](#F5){ref-type="fig"}). These improvements in locomotion with GR127935 or oxygen breathing lasted 10 - 30 min, consistent with the pO~2~ measurements and with the known washout time of intrathecal drug injections^[@R15]^. Consistent with the action of NSD1015 as an irreversible AADC inhibitor, its actions lasted for at least 24 hours, demonstrating sustained improvements in locomotor function with vessel dilation ([Fig 5e](#F5){ref-type="fig"}).

Discussion {#S9}
==========

Our results demonstrate several new concepts that fundamentally alter the understanding of spinal cord function and rehabilitation after SCI: (i) after SCI, pericytes play a major role in regulating capillary tone and blood flow in the spinal cord; (ii) SCI leads to a chronic state of excess capillary tone, poor blood flow and hypoxia; (iii) the monoamine receptors 5-HT~1B~ and α~2~ regulate capillary tone in the absence of the monoamines 5-HT and NA in transected cords; (iv) AADC expressed in capillary pericytes synthesize the TAs tryptamine and tyramine from physiological concentrations of dietary amino acids, and these TAs are responsible for monamine receptor activation**,** replacing the action of brainstem-derived monoamines lost with SCI, and (v) antagonism of monoamine receptors, inhibition of AADC enzyme function or augmentation of inhaled O~2~ or CO~2~ after SCI produces lasting improvements in blood flow and cord oxygenation, which ultimately improves motor function, including locomotion. Notably, we found that chronic spinal cord hypoxia occurs with clinically-relevant partial spinal cord injury (contusion injury) and that long-term improvement in locomotor function can be achieved with interventions that dilate vessels (e.g., AADC inhibitors). These results demonstrate that alleviation of chronic hypoxia is a promising approach to rehabilitation after SCI.

Our results also show that TAs produced endogenously from amino acids (via AADC) do *not* directly affect neuronal activity (see also ^[@R27]^), but instead act only on vessels caudal to the site of injury. Whereas exogenously applied TAs can directly affect neuronal function, via the 5-HT~2~ and TAAR receptors^[@R27]^, TAs endogenously produced in vessels are likely metabolized by MAO before they can diffuse to neurons^[@R23]^. Furthermore, the treatments we used to dilate capillaries after SCI---a selective 5-HT~1B~ antagonist (GR127935) and an AADC inhibitor---act primarily on pericytes rather than neurons, because they did not affect neuronal activity in isolated cords maintained *in vitro*. Additionally, GR127935 could not have directly affected locomotor or motoneuron function, because after severe SCI there is little to no 5-HT present to activate locomotor-related 5-HT receptors, and even if these receptors were somehow activated (by residual 5-HT in the contusion rats), the primary locomotor-related receptors include 5-HT~2A/C~ and 5-HT~1A~ receptors^[@R53]^, which are not antagonized by GR127935.

The concept that pericytes play a major role in controlling blood flow has only recently been described in the brain (cerebellum and retina)^[@R6],[@R7],[@R44],[@R45]^ and has not been previously demonstrated in the spinal cord. Pericytes and SMCs can both regulate CNS blood flow, but controversy exists as to whether pericytes or SMC play the primary role^[@R54]^, particularly as pericytes are highly diverse, with many containing α-SMA, but others not^[@R43]-[@R46],[@R54],[@R55]^. Our results demonstrate that capillary pericytes can play a primary role in regulating blood flow, because treatment with tryptophan after SCI induces widespread constrictions of capillary pericytes, but not of arterioles, via the action of AADC that is expressed exclusively in pericytes, and is not present in arterioles, arteries or SMCs^[@R14],[@R23]^ Furthermore, blocking the action of pericyte AADC (with NSD1015) or of associated TAs on the 5-HT~1B~ receptor (with GR127935) markedly improves blood flow, oxygenation and motor function *in vivo*. Although arterioles (with SMCs) express monoamine receptors and respond to exogenously applied monoamines (5-HT and tryptamine)^[@R11],[@R14],[@R36]^, AADC products produced by pericytes likely do not diffuse sufficiently far to influence distant arterioles or neurons^[@R23]^.

The marked chronic hypoxia (pO~2~ ∼10 mmHg) that we observed in the cord far caudal to the site of injury was unexpected, especially in the case of partial injury (contusion injury), as previous studies have focused on the acute stage of injury and the injury epicenter^[@R2],[@R16],[@R19],[@R43]^. In contrast to hypoxia caudal to the site of injury, the cord rostral to the injury is well oxygenated (28 mmHg), similar to that reported for the uninjured spinal cord and brain^[@R49]-[@R51]^. Based on these observations, any treatment that increases systemic blood flow or arterial pO~2~, including exercise^[@R53],[@R56]^, should also increase cord oxygenation and indirectly modulate neuronal function^[@R52]^, consistent with our findings after manipulation of blood pressure and inhaled O~2~ concentrations.

Chronic spinal cord hypoxia likely contributes to long-term disabilities that slowly emerge after SCI, including metabolic plasticity^[@R19]^, chronic spinal cord inflammation^[@R18],[@R47]^, long-term deterioration and loss of neurons^[@R57]^, and exhaustion during locomotor activity ^[@R58]^. Increasing cord perfusion (and pO~2~) may reduce these clinical problems, although the adverse effects of reactive oxidative species should be considered if oxygenation is abruptly increased^[@R1]^. Paradoxically, we found that transient hypoxic breathing produces a rebound increase in spinal pO~2~ that lasts \> 20 min, which might help explain why intermittent hypoxic breathing improves rehabilitation after SCI^[@R59]^.

Our finding that TAs control capillary tone, arguably represents the first time that *endogenous* TAs have been shown to have a stand-alone spinal cord function, in the absence of classical monoamines. Previously, secondary functions have been ascribed to TAs in the CNS involving their modulation of monoamine function^[@R25],[@R26]^, including TAs modulating the dopamine transporter, to compensate for reductions in dopamine^[@R33],[@R60]^. The latter dopamine mechanism, involves TAs acting on the *same* cell in which they are produced (the dopamine neuron). Similarly, our results suggest that TAs produced by AADC in pericytes act locally to induce constriction of the same pericyte. AADC is expressed densely in the pericyte, especially adjacent to the vessel wall, allowing for ready access to blood-borne tryptophan^[@R30]^ to produce tryptamine, which in turn diffuses throughout the pericyte (filling the soma) and acts on the 5HT~1B~ receptor on the pericyte itself to produce vasoconstriction ([Fig 2e](#F2){ref-type="fig"} schematic). Likely, this requires tryptamine to leave the pericyte (via a transporter like OCT^[@R27]^) to act extracellularly on 5-HT~1B~ receptors in the pericyte membrane, though we cannot rule out direct action on intracellular 5-HT~1B~ receptors^[@R27]^. After SCI, a few neurons also upregulate AADC expression^[@R23],[@R24]^, which may complement pericyte function in regulating vessel tone, since these neurons contact vessels^[@R23]^.

The remarkable adaptation of capillary pericytes to SCI is functionally similar to the adaptation of motoneurons to SCI: motoneurons become hyperactive due to paradoxical monoamine receptor activity, ultimately leading to muscle spasms^[@R15],[@R21]^. However, the mechanisms underlying the effects of SCI on pericytes and motoneurons are very different, as motoneurons upregulate isoforms of 5-HT~2C~ receptors that are constitutively active^[@R15]^, whereas pericytes upregulate AADC that produces TAs, leading to 5-HT~1B~ receptor activation.

Online Methods {#S10}
==============

All rat experiments were approved by the Health Sciences University of Alberta Animal Care and Use Committee. Most of the studies, except the locomotor-related studies, were performed using the sacral transected injury model, where the S2 sacral spinal cord was transected in adult female Sprague-Dawley rats at ∼ 2 months of age, as described previously^[@R15],[@R23]^. Briefly, under general anesthetic (sodium pentobarbital, 58.5 mg/kg, and isoflurane) and sterile conditions, a laminectomy was performed on the L2 vertebrae to expose the S2 spinal cord. The dura was slit transversely, and 0.1--0.3 ml Xylocaine (1%) was applied topically. Using a surgical microscope, the spinal cord was transected by holding the pia with forceps and removing tissue using suction (using a 1 cc syringe that had been melted and pulled to a fine tip). Caution was taken to avoid damaging the anterior artery or posterior/dorsal vein, since the sacrocaudal spinal cord dies without this midline vasculature. The dura was closed with two 8-0 silk sutures, the muscle layers and skin were tightly sutured over the cord, and the rat was allowed to recover. All experiments were performed 2 - 4 months post injury, when tail muscle spasticity was full developed and rats were considered to be in a chronic spinal state (chronic spinal rats)^[@R15]^. Chronic spinal rats were compared to age-matched normal uninjured rats (rats were randomly assigned to these two groups).

Contusion and staggered hemisection injury models were used for locomotion studies^[@R15]^. Under anesthesia with fentanyl (Hypnorm 120 μl/200g; Janssen, Canada) and midazolam (0.75 mg/200g; Sabex, Belgium), adult female Sprague-Dawley rats were injured at ∼ 6 weeks of age. Rats received either a severe contused injury at spinal T8 vertebrae (impact force 200 kDyn) or underwent a staggered hemisection. The latter rats were first hemisected on the right at the T10 spinal vertebrae (T10 -T11 cord level). Then two weeks later, rats received an over-hemisection on the left at spinal T7 - T8 vertebrae (T7-T8 cord). In this staggered hemisection model, all direct descending supraspinal inputs, including 5-HT fibers, are cut, whereas spared local propriospinal neurons relay descending signals around the lesion site (Fig-6a; [Supplementary Fig 16](#SD1){ref-type="supplementary-material"})^[@R15]^. This procedure allows for some spontaneous recovery of voluntary locomotion (unlike in transected animals) in the absence of 5-HT. Bladders were expressed 3 times daily for at least 3 days, until bladder function recovered. Locomotion was evaluated 3 - 5 weeks after contusion or the second hemisection using parameters of plantar foot placement, step frequency, and iliac crest height (hip; see below).

*In vitro* preparation {#S11}
----------------------

Under urethane anesthesia (1.8 g/kg, with a maximum dose of 0.45 g), the whole spinal cord caudal to the S2 injury level was removed from chronic spinal rats and immersed in oxygenated modified artificial cerebrospinal fluid (mACSF). For ventral root recording and reflex testing, the sacral S4 and caudal Ca1 ventral roots and the Ca1 dorsal roots were used, and remaining roots removed. For imaging vessels in the cord, all roots were removed from the cord. After 0.5 - 1.5 h in mACSF (at 20°C), the cord was transferred to a recording chamber containing normal ACSF (nACSF) saturated with carbogen (95% O~2~-5% CO~2~) and maintained near 21°C, with a flow rate of 5 ml/min. In some cords, pO~2~ was measured using the same sensor as used *in vivo* (Optode, see below), and the pO~2~ was adjusted to a desired level (cord pO~2~ : 10 - 50 mmHg) by mixing small amounts of N~2~ with the carbogen.

*In vitro* ventral root reflex recording and averaging {#S12}
------------------------------------------------------

Dorsal and ventral roots were mounted on silver-silver chloride wires above the nACSF of the recording chamber and covered with a 5:1 mixture of petroleum jelly and mineral oil for monopolar stimulation and recording. The dorsal root was stimulated with a single pulse (0.1 ms, 0.02 mA, 3×T \[reflex Threshold\]; repeated 5 times at 10 s intervals for one trial; trials repeated every 12 min), and the long-lasting reflex (LLR) response was recorded on the ventral roots, which corresponded to spasms *in vivo*, as previous described^[@R15]^. The ventral root recordings were amplified (2,000×), high-pass filtered at 100 Hz, low-pass filtered at 3 kHz, and recorded with a data acquisition system sampling at 6.7 kHz (Axonscope 8, Axon Instruments, Burlingame, CA). We quantified the LLR with custom-written software (MATLAB, MathWorks, Natick, MA) by averaging the rectified ventral root activity over a time-window of 500--4000 ms post stimulus, an interval corresponding to *in vivo* muscle spasms^[@R15]^. Because of slow diffusion in whole spinal cord preparations, drug treatment required 10-fold higher concentrations of the drug than are used in thin-slice preparations, and peak effects required 10--15 min. To assure selectivity of the drugs, they were titrated to a minimal dose that produced their peak effect, and results are reported at 10--45 min after drug application. Cumulative dose-response relations were computed by increasing drug doses at 12 min intervals (at doses of 0.003, 0.01, 0.03, 0.1 μM, down to 1 nM). The effects of drugs on the LLR were reversible on washout of the drug, but full recovery to baseline occurred only after several hours (data not shown), likely because of the large size of the whole cord preparation. Thus, washout of drugs was not feasible between doses of the drugs used in the construction of their dose-response curves.

IR-DIC microscopy of vessels, *in vitro* {#S13}
----------------------------------------

The sacrocaudal spinal cord was removed from rats, put in a recording chamber and imaged using an infrared differential-interference-contrast (IR-DIC) microscope (Leica Axioskop2 FC Plus); the cord was maintained in nACSF, as described above in the section above. Spinal capillaries were imaged both in the dorsal horn of the whole sacrocaudal cord preparation (viewing through the dorsal surface, 200 - 300 μm below the pia), and throughout the cord in transverse sections or sagittal hemisected cords (0.5 mm transverse sections were cut on a vibratome; sagittal hemisection performed by pulling the cord gently in half from rostral to caudal). Similar results were obtained for all methods of imaging spinal capillaries, and so the data using all methods were combined. Spinal capillaries that were chosen for imaging were mostly in thin sacral S4 and coccygeal Co1 segments where light could readily traverse the tissue, with the following criteria for capillary identification: 1) they had a diameter of \<11 μm; 2) they were located deep under the pia and white matter axons, assuring that they were not pial vessels; 3) they lacked continuous smooth muscle coverage as seen on arterioles; and 4) they were wrapped with sparsely-spaced, hemispherical-shaped pericytes. We analyzed pericytes on straight stretches of capillaries^[@R6]^, where drug-induced constrictions were maximal, rather than at vessel branch points, which had pericytes that did not always constrict. Drug application was the same as for *in vitro* root reflex recording methods. For normal rats we applied tryptophan (n = 24 vessel preparations) and 5-HT (*n* = 7). For chronic spinal rats we applied tryptophan (at 3 doses:10, 30 and 100 μM; *n* = 6, 34 and 44), phenylalanine (*n*=22), tyrosine (*n* = 20), 5-HTP (*n* = 23), tryptamine (*n* = 19), NSD1015 (with tryptamine or tryptophan; *n* = 16 each), GR127937 (with tryptamine or tryptophan, *n* = 10 and 21), zolmitriptan (at 2 doses, 3 and 300 nM; *n* = 8 and 10), RX821002 (with tyrosine, *n* = 5). Doses not provided here are quoted in the text or figure legends. Video was taken of vessels with an infrared camera and streamed to a computer via a high-definition video H.264 recorder (Blackmagic Design), and vessel diameter computed offline at common focal planes, before and after drug application effects reached steady state (5 - 10 min).

Spasms in awake chronic spinal rats {#S14}
-----------------------------------

Tail muscle activity and spasms were evoked with brief electrical stimulation of the skin of the tail tip and recorded with tail muscle EMG. Percutaneous EMG wires (50 μm stainless steel, Cooner Wires) were inserted in segmental tail muscles at the midpoint of the tail, and recordings were made while the rat was in a Plexiglas tube, as detailed previously^[@R15]^. Muscle spasms (long-lasting reflexes; LLR) were evoked with electrical stimulation of the skin at the distal tip of the tail (percutaneous stimulation; 0.2 ms, 10 mA pulse; 50 reflex threshold \[50 × T\]; spasms evoked at 40 s intervals), and the tail was partly restrained from moving with a piece of masking tape connecting the midpoint of the tail to a rigid stand. EMG was sampled at 5 kHz, rectified and averaged over a 500 to 4,000 ms interval to quantify spasms (LLR) using an Axoscope instrument (Axon Instruments) and MATLAB software (MathWorks). EMG over the period of 300 ms prior to stimulation was also averaged (background EMG). Drugs were dissolved in sterile saline and applied *in vivo* in chronic spinal rats by both intraperitoneal (i.p.) and intrathecal (i.t.) injections, and EMG was recorded both before and after drug injection. In other chronic spinal rats, the inhaled air was transiently switched to 95% oxygen (with 5% CO~2~) for 60 s, or to 10% CO~2~ (in air for 30 s). Both gases were delivered into the plexiglass tube holding the rat.

Spinal vascular imaging and blood flow, *in vivo* {#S15}
-------------------------------------------------

To evaluate blood flow rate in capillaries, *in vivo* two-photon laser scanning microscopy (TPLSM) was performed in chronic spinal rats^[@R48]^. Briefly, rats were anesthetized with urethane (1.8 g/kg, with a maximum dose of 0.45 g), and then a laminectomy was performed for T10-L4 vertebrae to expose the injured sacrocaudal spinal cord and the uninjured lumbar spinal cord. The exposed spinal segments were bathed in 0.9% saline and the rat was positioned under the microscope with a stereotactic frame stabilizing the vertebrae. Fluorescein isocyanate-dextran (FITC-dextran; 70,000 MW, Sigma-Aldrich) was injected via the lateral tail vein (0.3 mL, 5% \[w/v\] in saline), after warming the tail in water to dilate the vein. *In vivo* TPLSM was performed to track RBC velocity in capillaries (8 - 11 μm diameter), using a Leica SP5 MP TPLSM microscope and a Coherent Chameleon Vision II pulse laser tuned to 800 nm. Z-stacks and line scans through the first 200-400 μm of dorsal horn spinal tissue were acquired through the spinal preparation using a 20× 1.0 N.A. water-dipping objective. RBC velocity measurements were made from line scans using Leica MM AF software, with a high frame rate adequate to accurately estimate velocity (∼ 500 fps)^[@R48]^. Velocity was estimated before and after NSD1015 (dissolved in saline) was topically applied to the spinal cord. Velocity was measured in sections of the capillary between pericytes, chosen to be without obvious overall vessel diameter changes, so that the velocity corresponds to the overall capillary flow rate (volume).

We also measured global blood flow rates, using dye injection methods, in chronic spinal rats in the cord below the injury as compared to above the injury, and as compared to normal uninjured rats. Rats were anesthetized and laminectomy performed, as in the *in vivo* TPLSM experiments, to expose the lumbar and sacrocaudal spinal cord, which was filmed using a Panasonic G3 digital camera with a Leica macro-lens. Then rats were perfused intracardially with the vital dye methylene blue (5% Methylene blue solution, 1 g/ml, Sigma) in saline at room temperature using gravity-fed perfusion (at a height of 1.1 m to provide a common blood pressure close to normal; ∼90 mmHg). Global flow above and below the site of injury was estimated by the time taken for the methylene blue to turn major dorsal surface vessels blue (including the dorsal vein; the time at which the blue signal intensity quantitatively reached 90% of maximum steady state value), thus assuring that the dye fully traversed spinal capillary beds and filled the venous return. Video images were processed in ImageJ. GR127935 (30 μM in saline absorbed into a 4 mm^[@R3]^ piece of Gelfoam, Tocris) was applied locally onto the sacrocaudal spinal cord 5 min before perfusion (by putting the Gelfoam on the cord). For nitric oxide (NO) control experiments, rats were perfused for 2 min (via a pump) with ∼100 ml oxygenated nACSF containing the NO donor sodium nitrite (1 g/l; Fisher) and heparin (300 IU/l) to pre-dilate the vessels. Then the perfusion solution was switched to the 5% methylene blue solution (gravity-fed), and the time taken for cord perfusion was again measured. We have previously anecdotally noticed that, after SCI, the cord caudal to the injury was perfused poorly during preparation for histology, and thus the above methylene blue experiments were initially motivated by these observations. As we found that sodium nitrite in oxygenated nACSF reversed this poor flow problem (see Results), sodium nitrite in nACSF was injected into some rats prior to fixation to improve immunolabeling (see below).

Oxygen concentration measurements, *in vivo* {#S16}
--------------------------------------------

Oxygen concentrations were measured in normal uninjured and SCI rats *in vivo*. Anesthesia (urethane), laminectomy and stereotactic stabilizing were similar to the setup for spinal vascular imaging, described above. The partial pressure of oxygen (pO~2~) in the spinal cord was measured with an optical sensor^[@R49]^ (Optode, MicroOptode; Unisense) with a 50 μm tip coated with a fluorophore that when excited with 610 nm red light pulses emitted 780 nm infrared light that varied in intensity proportionally to the concentration of nearby oxygen quenching this light (where 1 μM O~2~ = 0.62 mmHg pO~2~; calibrated with a VetStat blood gas analyzer in serum, saline and nACSF). The sensor was mounted on a micromanipulator to advance the probe vertically to the dorsal cord surface. The probe either penetrated the pia and then penetrated deep into the grey matter of the dorsal and ventral horn, or dimpled the pia without penetrating it (by \> 200 μm) in the dorsal horn; similar pO~2~ measurements were obtained with either method. The pia dimple method (as diagrammed in [Fig-3d](#F3){ref-type="fig"}) caused less local damage and was thus preferred. Oxygen (pO~2~) was measured in the cord caudal to the SCI (*n* = 52; sacral cord), and compared to that rostral to the SCI (*n* = 39; lumbar cord) and in uninjured rats at equivalent sacral and lumbar regions (*n* = 34 and 12, respectively). Drugs were dissolved in saline and applied topically onto the cord, in normal rats (GR127935, *n* = 7; RX821001, *n* = 15; NSD1015, *n* = 6) and in chronic spinal rats (GR127935, *n* = 8; RX821001, *n* = 14; NSD1015, *n* = 16). Arterial blood gases (from the carotid artery: pO~2~, pCO~2~, pH and hemoglobin oxygen saturation \[Sat\] were measured; VetStat, IDEXX), end tidal CO~2~ (CWE, CapStar-100) and respiration rate were monitored to assure that they were in their normal ranges (95 - 105 mmHg, 35 - 45 mmHg, 7.3 - 7.4, 94 - 96%, 3.5 - 4.5% and 60 - 80 bps, respectively), and as necessary were maintained with artificial respiration (via a trachea tube and respirator, CWE SAR1000). Under standard conditions, rats inhaled room air. As a control to test the sensitivity of the spinal cord pO~2~ measures, rats briefly (∼1 min) inhaled differing mixtures of O~2~ and CO~2~, including: oxygen (100%, *n* = 7; hyperoxia; arterial blood gas pO~2~: 390 mmHg, pCO~2~: 35 mmHg; Sat:100%), carbogen (95% O~2~, 5% CO~2~; *n* = 20; blood gas pO~2~: ∼350 mmHg, pCO~2~: 50 mmHg; Sat: 100%), air with 10.5% O~2~ (10.5% O~2~, 89.5% N~2~; *n* = 7; hypoxic condition; blood gas pO~2~: 50 mmHg, pCO~2~: 28 mmHg; Sat: 81%), or air with 10% CO~2~ (*n* = 5; hypercapnia condition; blood gas pO~2~: 91 mmHg, PCO~2~: 57 mmHg; Sat: 93%). Blood gases rapidly returned to normal (within 1 - 2 min) after these manipulations. There were also rapid proportional changes in spinal cord pO~2~ as arterial pO~2~ changed, though the spinal pO~2~ showed sustained increases in pO~2~, outlasting the arterial changes (see Results). Also, when the sacral spinal cord blood flow was acutely terminated at the end of the experiment (by transection), the spinal cord pO~2~ dropped to zero within a few seconds. These inhaled gas and blood flow manipulations were routinely used to confirm the calibration and functioning of the pO~2~ measurement device.

Locomotion analysis and i.t. drug injections {#S17}
--------------------------------------------

Rats with high thoracic contusions or staggered-hemisections were filmed with a high-speed digital camera (Panasonic, 120 frames/s) while walking across a 1.5 m long Plexiglas runway with a mirror underneath, with markers on their hindlimbs to estimate hip (iliac crest), knee, ankle, and foot (fifth metatarsal) position. The following parameters were used to evaluate locomotion: 1) weight support (height; hip height minus torso width, equivalent to torso clearance above the ground), 2) leg extensor spasms (quantified as the time that the foot over-extends and drags immobile on its dorsal surface, relative to step-cycle duration), 3) plantar steps (the number of plantar steps counted relative to the number of front steps) and 4) foot placement in stance (measured as foot deviation behind the hip at onset of stance). Walking step-cycle cadence was defined by the front legs (front-leg steps/sec) and was chosen to be similar before and after treatments with oxygen or GR127935. To inhale oxygen, rats were put into a chamber filled with 95% O~2~ (carbogen, not pressurized) for 90 s. GR127935 was given intrathecally (i.t., with one exception given i.p. at 8 mg/kg). The i.t. injection was done under very brief isoflurane anesthesia as previously described^[@R21]^. That is, a standard 26 gauge injection needle (5/8 in) connected to a Hamilton-syringe was inserted by sliding the needle down the caudal aspect of the L5 vertical process to a small opening between the L5 and L6 vertebrae (at cauda equina), obtained by lifting the hips 5 - 10 cm with one hand (rostral) while injecting with the other (caudal). Rats received isoflurane and a saline i.t. injection (30 μl) as a control and 1 h later a drug i.t. injection (GR127935, 10 mM, 30 μl, dissolved in sterile saline) in one experimental session. We quantified walking in control and drug treated rats at ∼5 - 30 min after the i.t. injection, long enough for the rat to be fully alert (rats awoke and walked in \< 2 min), but prior to washout of the i.t. injected drugs. A group of rats with contusions also received an i.t. injection of NSD1015 (100 mM in 30 μl), and its effects were determined at 1 and 24 h after injection.

The BBB score is a qualitative 1 - 20 scoring system useful for studying the progression of locomotor recovery as rats go from no walking ability acutely after injury to moderately improved walking in the chronic SCI state. However, in the chronic injured state of severely injured animals, like we studied, the BBB score is much less useful for detecting further improvements in locomotion, because the score saturates and is insensitive to improvements. Specifically, once rats can make occasional weight-supported plantar steps they have a score of 10 and to go beyond 11 they need to coordinate the forelimb and hindlimbs, which never happens after severe injury. Thus, in the chronic SCI state rats remain at about a score of 11, regardless of treatment. Thus, we could not use this score.

Drugs and solutions {#S18}
-------------------

Two kinds of ACSF were used in *in vitro* experiments: mACSF in the dissection dish before recording and nACSF in the recording chamber. mACSF was composed of (in mM) 118 NaCl, 24 NaHCO~3~, 1.5 CaCl~2~, 3 KCl, 5 MgCl~2~, 1.4 NaH~2~PO~4~, 1.3 MgSO~4~, 25 [d]{.smallcaps}-glucose, and 1 kynurenic acid. nACSF was composed of (in mM) 122 NaCl, 25 NaHCO~3~, 2.5 CaCl~2~, 3 KCl, 1 MgCl~2~, 0.5 NaH~2~PO~4~, and 12 [d]{.smallcaps}-glucose. Both types of ACSF were saturated with carbogen (95% O~2~-5% CO~2~) and maintained at pH 7.4. The drugs added to the nACSF were 5-HTP, clorgyline, pargyline, tryptamine, L-tryptophan, tyramine, L-tyrosine, 2-phenylethylamine, L-phenyalanine, NSD1015 (Sigma-Aldrich), α-methyl-5-HT, octopamine, SB206553, RX821002, GR127935, dobutamine, vasopressin (Tocris) and zolmitriptan (AstraZenica). All drugs were first dissolved as a 10 -- 50 mM stock solution in water before final dilution in ACSF for *in vitro* ventral root reflexes recording and DIC microscopy or in saline for *in vivo* oxygen measurements and two photon microscopy, with the exception of zolmitriptan, which was dissolved in minimal amounts of DMSO (DMSO final concentration in nACSF was 0.04%). DMSO alone had no effect on *in vitro* LLR in vehicle controls, as compare to nACSF control state.

mRNA analysis {#S19}
-------------

Gene expression for pericyte-related signaling proteins (including CD13, encoded by *Anpep*) was determined from data generated by our recent RNA-seq study of 8 chronic spinal rats (sacral spinal) and 8 age-matched control animals, which were sacrificed 8 weeks after SCI^[@R47]^. Briefly, mRNA was extracted from the whole sacral cord caudal to the SCI site (sacral S2, not including tissue at the site of injury) for each rat sample. This was converted to cDNA, amplified with PCR and sequenced, yielding a library of 14 million mRNA sequences per rat sample. Sequences were compared to the rat genome version rn4 obtained from UCSC, and the number of mRNA sequences corresponding to each gene was counted, with 15,000 different genes detected. To compensate for variability in the amount of total mRNA isolated in each sample, library-size-adjusted read counts were obtained using the 'estimateSizeFactors' function of the DESeq R package ([Supplementary Figure 12](#SD1){ref-type="supplementary-material"}). Differentially expressed (DE) genes after SCI were defined as those with fold change of \> 1.2 or \< 0.8 (for positively and negatively DE genes, respectively) and with a false discovery rate adjusted p value \< 0.05.

Immunolabeling {#S20}
--------------

Rats were euthanized with Euthanyl (BimedaMTC; 700 mg/kg) and perfused intracardially with 100 ml of saline containing sodium nitrite (1 g/l; Fisher) and heparin (300 IU/l, from 1,000 U/ml stock; Leo Pharma) for 3--4 min, followed by 400 ml of 4% paraformaldehyde (PFA; in phosphate buffer at room temperature), over 15 min. Spinal cords were postfixed in PFA overnight at 4°C, cryoprotected in 30% sucrose in phosphate buffer, frozen, and cut on a NX70 cryostat (Fisher Scientific) in horizontal or transverse 20 μm-thick sections. We mounted spinal cord sections on slides and rinsed with Tris-buffered saline (TBS, 50 mM) containing 0.3% Triton X-100 (TBS-TX, 3× 15 min rinses used for all TBS-TX rinses). Sections were incubated overnight at 4°C with the following primary antibodies in TBS-TX: rabbit anti-5-HT (1:5,000; Sigma S5545), mouse anti-glial fibrillary acidic protein (GFAP) (1:500; Millipore MAB360), mouse (1:200; Millipore MAB5384) and rabbit (1:200, Millipore; AB5320) anti-NG2 Chondroitin Sulfate Proteoglycan, rabbit anti-Tryptamine conjugated to glutaraldehyde (1:1000; Advanced Targeting Systems AB-T04), rabbit anti-5-HT~1B~ (1:100; Abcam AB13896), goat anti-Aminopeptidese N/CD13 (CD13, 1:250; R&D systems AF233), rabbit Anti-von Willebrand Factor (VF, 1:100; Millipore AB7356), and sheep anti-AADC (1:200; Millipore AB119). The slides were rinsed again in TBS-TX. For staining of AADC, antigen retrieval was performed by incubating slides in 10 mM citrate buffer (pH 8.5) at 80°C for 30 min prior to primary antibody incubation^[@R23]^. For staining of 5-HT~1B~, antigen retrieval was performed by immersing slides in TBS with 0.05% tween 20 (pH 9) at 80°C for 40 min; then after 20 min at room temperature, slides were incubated 1 hr with 10% normal goat serum (NGS; Vector, S-1000; blocking procedure). For staining of tryptamine, rats were instead perfused with 0.5-1.0% glutaraldehyde (GA) and 4% formaldehyde (FA) and postfixed in the same GA/FA solution overnight, and cut in transverse sections as before. Then spinal sections (on slides) were incubated in 1% sodium borohydride for 20 minutes, and then underwent 1 h blocking in 10% NGS (Vector, S-1000; or normal donkey serum) in TBS-TX at room temperature. Finally, all sections (for all antibodies) were incubated overnight in TBS-TX with 1% NGS at room temperature. To visualize the labeling of 5-HT, VF, CD13, GFAP, 5-HT~1B~ and NG2, fluorescent secondary antibodies were used, including goat anti-rabbit Texas red (1:200-1:500; Vector T-1000), goat anti-mouse Alexa Fluor 488 (1:200-1:500; Invitrogen A11029), donkey anti-rabbit Alexa Fluor 488 (1:200; Abcam AB1501529), and donkey anti-rabbit Alexa Fluor 555 (1:200, Abcam AB150174) in TBS-TX, applied on slides for 2 h at room temperature. To visualize AADC with fluorescent methods, tyramide amplification was sometimes performed (Invitrogen TSA Kit no. 12), which included tyramide, ABC amplification, and biotinylated Alexa Fluor 488 (Vector PK-6101) or Alexa Fluor 647 (1:200, AB150179; donkey anti-sheep). Alternatively, to view DAB labeling of AADC or tryptamine, biotinylated donkey anti-sheep secondary antibody (1:2,000; Millipore AP184B) or goat anti-rabbit secondary antibody (1:200; Vector ABC kit) was applied at room temperature for 2 h in TBS-TX, followed by DAB-ABC amplification according to the manufacturer\'s guidelines (ABC, Vector PK-6101; DAB, Vector SK-4100). At times, an 0.1% cresyl-violet counter-stain (1 min incubation) was applied with tryptamine DAB staining. After rinsing with TBS-TX, the slides were serially dehydrated with alcohol, cleared with xylene, and coverslipped in Permount (Sakura Finetek USA, Torrance, CA, USA). Image acquisition was performed by both conventional microscopy (for DAB) and confocal microscopy with a Leica TCS SP2 II Spectral Confocal System (for fluorescence). The latter used 1.3 μm optical sections that were collected into a *z*-stack of 5--20 μm and subsequently projected into a single image with maximum-intensity sorting (with ImageJ).

To quantify the function of AADC, we measured the AADC-mediated production of 5-HT in chronic spinal rats injected with 5-hydroxytryptophan (5-HTP), followed by fixation for immunolabeling. 5-HT synthesis is a useful surrogate marker of AADC and tryptamine production, because: 1) 5-HT is completely absent after spinal transection^[@R23]^ (and loss of brainstem innervation); 2) exogenous application of 5-HTP, 25 - 30 min prior to fixation, leads to 5-HT synthesis by AADC that is readily visualized with 5-HT immunolabeling^[@R23]^; 3) 5-HT is a tryptamine analog (5-hydroxytryptamine) equally well produced by AADC, compared to tryptamine, so the OH^-^ group on 5-HT can be viewed as a marker that allows us to image tryptamine production; and 4) the 5-HT antibody is readily combined with other antibody labelling (NG2), because it does not rely on glutaraldehyde (GA) fixation, unlike the tryptamine antibody which binds only to glutaraldehyde-conjugated tryptamine and thus requires GA fixation, which is not compatible with many other antibodies (NG2).

In general, we found that antibody binding and labeling was reduced in over-fixed tissue, especially in vasculature that necessarily received the most direct fixative during perfusion fixation. Thus, rather than our standard procedure of perfusing vessels with fixative, vessel labeling with some antibodies (NG2, tryptamine, 5-HT, AADC) was confirmed and improved by an alternative method: after rinsing out the blood from cords by perfusion with ASCF with sodium nitrite (2 min; see above), the cords were directly immersed in fixative (e.g. 4 % PFA), or were perfused with a lower concentration of PFA (2%). This over-fixation problem likely explains the quantitative discrepancies in the literature seen for expression of AADC and its products in vessels^[@R23],[@R24]^. Standard controls in which the primary antibody was omitted were used to confirm the selectivity of the antibody staining. Also, clear labeling of monoamine fibers in normal rats was used as a positive control for AADC and 5-HT staining, and loss of these fibers in chronic spinal rats was used as a negative control.

Data analysis {#S21}
-------------

Data were analyzed in Clampfit 8.0 (Axon Instruments, USA) and Sigmaplot (Jandel Scientific, USA) software. Data are mostly presented as box plots, with a box and horizontal bar within representing the interquartile range and median, respectively. Whiskers (error bars) extend to the most extreme data point that is within 1.5 times the interquartile range from the box. When there are less than ten data points then individual data points are shown ([Fig 5](#F5){ref-type="fig"}) or error bars represent one standard deviation from the mean ([Fig 4](#F4){ref-type="fig"}). Elsewhere data is quoted as mean ± standard error mean (s.e.m.), as indicated. A Student\'s *t*-test was used to test for statistical differences before and after treatments, or between normal and injured rats, with a significance level of *P* \< 0.05. Power of tests was computed with α = 0.05. A Kolmogorov-Smirnov test for normality was applied to each data set, with a *P* \< 0.05 level set for significance. Most data sets were found to be normally distributed, as is required for a *t*-test. For those that were not normal a Wilcoxon Signed Rank Test was instead used with *P* \< 0.05.
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![Trace amines constrict capillaries at pericytes after SCI. **(a)** Schematic of the spinal cord vasculature. **(b)** Immunolabeling for pericytes (NG2, p) on a spinal capillary (v) and nearby astrocytes (GFAP, a) caudal to the site of SCI. **(c)** Schematic of the DIC microscopy set-up used to image capillaries deep below the pial surface of cord after SCI. **(d)** Top, DIC image of capillary in the spinal cord caudal to a chronic sacral transection, with RBCs (R) and the lumen pseudo-colored red for clarity (arrows point to the endothelium). Bottom, application of tryptophan (30 μM) induced a tonic local vasoconstriction (white arrows; starting 1 min post application) adjacent to a pericyte (p), but not in regions lacking pericytes (black arrows). **(e)** Same as d, but with AADC inhibitor (NSD1015 \[NSD\]; 300 μM) applied prior to tryptophan, to prevent tryptamine production. **(f)** Tryptamine application mimicked tryptophan-induced vasoconstriction (d), adjacent to pericytes (outlined in green). **(g)** Tryptophan-induced constriction (top, at arrows) reversed by 5-HT~1B~ receptor antagonist GR127935 (3 μM; bottom). **(h)** Capillary in normal rat (top), lacking tryptophan-induced constrictions (bottom). (**i**) Plots of group data for capillary diameters (normalized to pre-drug control) after bath application of amino acids (10, 30, 100 μM tryptophan \[trypto10, trypto30, trypto100\], 30 μM tyrosine \[tyro\], 50 μM phenylalanine \[phenyl\], or 0.1 μM 5-HTP), AADC products (10-100 μM tryptamine \[trypta\], or 0.3 μM 5-HT) or zolmitriptan (3 and 300 nM: zolm3 and zolm300), with and without inhibition of AADC (NSD1015) or antagonism of the 5-HT~1B~ and α~2~ receptors (with GR127935 and 0.5 μM RX821002, respectively) are shown, and *n* values are detailed in the Methods. Right plot, arteriole diameter with tryptophan. \* *P* \< 0.05: significant change relative to pre-drug control (100%). \# *P* \< 0.05 relative change with antagonist or blocker. Box plots and horizontal bar within represent the interquartile range and median, respectively. Error bars extend to the most extreme data point that is within 1.5 times the interquartile range.](nihms863891f1){#F1}

![AADC, trace amines and 5-HT~1B~ receptors are co-expressed in pericytes after SCI. **(a)** Top, immunolabeling with an AADC antibody (black, DAB, upper panel) in a transverse section of a spinal cord caudal to a chronic spinal transection, showing that AADC is widely expressed on capillaries (v), but not arteries (a). Bottom, immunofluorescence for AADC (red) and CD13 (green, pericyte marker) in a lengthwise section of capillary, showing exclusive colocalization of AADC and CD13 in pericytes (p; yellow). **(b)** Left, DAB immunolabeling of endogenous tryptamine (black) caudal the site of injury, showing dense staining for tryptamine in pericytes (arrows) of capillaries (v), especially in the soma. Inset shows a higher magnification view of a capillary cross-section (scale bar, 10 μm), showing that pericyte (p) cell bodies and processes stain for tryptamine (arrows), but an endothelial cell (e) does not (blue, cresyl-violet stain of the endothelial cell nucleus). Right, immunofluorescent staining for tryptamine (red) and CD13 (green) further showing tryptamine staining in a pericyte. **(c)** Immunolabeling for the AADC product 5-HT and for the pericyte marker NG2 caudal to a chronic transection injury after pre-treatment with 5-HTP (30 mg/kg, i.p., 25 min prior to fixation). Arrows, staining of 5-HT in NG2-labeled pericytes. **(d)** This AADC product 5-HT (red) is shown densely accumulated in pericyte cell bodies and processes labelled for AADC (green; at arrows). **(e)** Schematic of pericyte action on capillaries after SCI, showing diffusion of tryptophan (red) from blood into pericytes, synthesis of tryptamine (yellow) from AADC, and the action of tryptamine on nearby 5HT~1B~ receptors (blue) to constrict the capillary. **(f)** Immunolabeling for 5-HT as in panels **c** and **d**, but without 5-HTP pre-treatment. **(g)** Immunolabeling for the 5-HT~1B~ receptor and NG2 caudal to the site of injury. Arrows show localization of 5-HT~1B~ receptor on NG2-labelled pericytes, with dense areas of receptor staining on pericyte processes. *n* = 5 rats tested per condition.](nihms863891f2){#F2}

![Poor blood flow and hypoxia after chronic SCI. **(a)** *In vivo* images of sacral and lumbar spinal cord dorsal vasculature in normal and chronic spinal rats, before and after (20 and 40 s) intracardial injection of methylene blue dye (2% in saline). **(b)** Perfusion times in sacral (S, caudal to injury) or lumbar (L, rostral) cords of injured and normal uninjured rats, and changes with the 5-HT~1B~ antagonist GR127935 (GR, 30 μM topically applied to caudal cord) or sodium nitrate (NO donor; see Methods); *n* = 5 rats per group in box plots. **(c)** Top, two-photon microscopy image of the *in vivo* sacral spinal cord vasculature caudal to the site of injury, after FITC-dextran injection (i.v.). The arrow indicates location of a sub-pial spinal capillary imaged. Bottom left, higher magnification and brightened view of the indicated capillary where RBC flow computed. Bottom right, box plots of group capillary RBC flow rate in untreated and NSD1015 (NSD)-treated spinal cords (3 mM topically administered) in chronic spinal rats, *n* = 5 per group. **(d)** Schematic of *in vivo* oxygen measurement (pO~2~) in the spinal cord. **(e)** Low pO~2~ caudal to chronic SCI (hypoxia, red), compared to rostral to the SCI or in normal uninjured rats, and changes in pO~2~ after dilating vessels with NSD1015 or GR127935 (GR, topical 30 μM), or transient high O~2~ breathing (95% O~2~, with 5% CO~2~ for 1 min). **(f)** Box plots of pO~2~ in uninjured (normal) and injured rats before and after treatments with transient oxygen (95% for 1 min; measured at 10-20 min), GR127935, RX821002 (RX; 5 μM topical), or NSD1015 (NS); *n* = 5 - 20 per treatment, as detailed in the Methods. Drug effects peaked within minutes and sustained for the duration of the recording 10 - 90 min (peak reported); pO~2~ values are means from L4--L6 (rostral to injury or normal lumbar) and S2--S4, Ca1 (caudal to injury or normal sacral) spinal segments. \**P* \< 0.05, significant difference relative to pre-treatment control (f) or normal tissue (b).](nihms863891f3){#F3}

![Treatments that dilate vessels and improve oxygenation after SCI lead to increased motor activity. **(a)** Schematic of awake chronic spinal rat in Plexiglas bottle for tail muscle EMG recording and electrical stimulation of the tip of the tail (50×T) to evoke reflexes. **(b)** Representative muscle activity in a chronic spinal rat, showing baseline EMG activity prior to stimulation (arrow) and long-lasting reflex (LLR) evoked by stimulation, before (top) and after GR127935 treatment (bottom) (intrathecal \[i.t.\], 30 μl, 10 mM). **(c)** Box plots of the change in the LLR measured *in vitro* (rectified-average) induced by blocking the TA-mediated vasoconstriction of capillary flow with either GR127935 (GR, i.p. 8 mg/kg, *n* = 3 or i.t. 10 mM in 30 μl; *n* = 2; combined) or RX821002 (RX, i.p. 1 mg/kg, n = 11; or i.t. 3 mM in 30 μl, *n* = 5), and compared to the change in LLR studied in the isolated *in vitro* spinal cord, with application of GR127935 (3 μM, *n* = 18), RX821002 (1 μM, *n* = 42) and NSD1015 (NS, 300 μM, *n* = 9) (see [Supplementary-Fig-15](#SD1){ref-type="supplementary-material"}). LLR normalized to LLR prior to drugs, 100%. **(d)** Representative EMG trace in a chronic spinal rat before and 15 min after transient breathing of 95% O~2~ (1 min, with 5% CO~2~). Smoothed rectified rhythmic activity is indicated by the blue line. **(e)** Time course of mean LLR before and after transiently increased O~2~ breathing *in vivo* (1 min), compared to LLR response to increased O~2~ in the isolated *in vitro* spinal cord (pO~2~ increased in nACSF). **(f)** Box plots of LLR in injured rats *in vivo*, either prior to treatment (Pre), during treatment with O~2~ or CO~2~, or 10--20 min post-treatment (post). Treatments were transient hyperoxia (O~2~, 95% for 1 min, *n* = 8) or hypercapnia (CO~2~, 10% in air for 30 sec, *n* = 10) breathing. Also shown are data for *in vitro* isolated spinal cords during or after treatment with O~2~ (*n* = 6). All conditions normalized as in c. \* *P* \< 0.05 significant difference relative to pre-drug condition.](nihms863891f4){#F4}

![Thoracic contusion or staggered hemisection injury induces chronic hypoxia that impairs locomotion. (**a**) Schematic of thoracic staggered-hemisection SCI, which transects all descending axons from the brain, including those containing monoaminergic neurons. (**b**) Video image sequence of a rat walking one month after receiving a staggered hemisection injury. Impaired hindlimb function while walking is evident from poor weight support (quantified as torso height above ground), leg extensor spasms (quantified as spasm time relative to step-cycle duration), slow steps (number of hindlimb plantar steps per step-cycle of front leg) and poor foot placement (caudal to behind hip). Hip (iliac crest), knee and ankle joints are shown with dots and lines. Arrow shows foot movement. **(c)** Effects of intrathecal application of GR127935 (10 mM in 30 μl) on locomotion, with locomotion phases annotated above. **(d)** Plots of mean locomotor parameters for each rat (circles) with staggered hemisection injury (3 - 5 weeks post injury), including body height, extensor spasm time, number of successful hindlimb steps and foot placement error, before and after application of GR127935 or transient breathing of 95% O~2~ (90 s; with 5% CO~2~; measured 10--15 min post treatment). *n* = 7 rats per treatment group. Error bars: s.e.m, bars: group means **(e)** Plots of mean locomotor parameters for each rats with contusion injury, in a similar format as **d**. Effects 1 and 24 h after treatment with NSD1015 (100 mM in 30 μl i.t.; NSD) were also measured. *n* = 9 rats for GR127935 and oxygen, and *n* = 6 for NSD. **(f-g)** Plots of pO~2~ in uninjured (normal) rats (lumbar cord) and in SCI rats (caudal \[lumbar\] and rostral \[thoracic\] to the site of injury), before and 10-15 min after treatments with transient oxygen (95%, 90 s), GR127935 (GR, topically applied 30 μM), or RX821002 (RX, topical 5 μM). \**P* \< 0.05: difference relative to normal cord or change with treatment.](nihms863891f5){#F5}

###### Editorial summary

In rat models of spinal cord injury, the region of the spinal cord below the site of injury becomes hypoxic due to inadequate blood flow, due to increased production of neurotransmitters known as 'trace amines' that act on pericytes to constrict blood vessels. Alleviation of hypoxia by hyperoxic breathing or inhibition of trace amine synthesis or action improves locomotor function in the injured rats.
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